Primer: Corona Remedies (CORONA IN) - Aug 2026
Corona Remedies is a rapidly growing, India-focused pharmaceutical company with a strong position in high-growth chronic and sub-chronic...
Corona Remedies IPO Review: Rolling up Growth
CRL focuses on chronic therapies for Women's healthcare and cardio-diabetics, with a diverse portfolio of 550+ products. It follows a roll-up...
Corona Remedies IPO: Well-Positioned for Multi-Year Profitable Growth
Corona Remedies IPO will open for subscription on December 8 and close on December 10. The IPO price band has been set at INR1,008–1,062 per share....
IPM Pharma Pulse March-25: Driven by Semaglutide Generics; Low Single Digit Growth Outlook for FY27
IPM sees 11% YoY growth in Mar 2026, driven by Semaglutide generics and GLP-1 market surge. Jan Aushadhi's expansion poses challenge to branded...
Insider Activity: Who Bought Their Own Stock in August 2026 ?
September 2026 is witnessing an increase in insider buying transactions before the earnings season starts next month. Few notable names coming up...
No more insights